ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000260

Epigenetic programming of neurodegenerative diseases by an adverse environment

Identifieur interne : 000260 ( PascalFrancis/Corpus ); précédent : 000259; suivant : 000261

Epigenetic programming of neurodegenerative diseases by an adverse environment

Auteurs : Olena Babenko ; Igor Kovalchuk ; Gerlinde A. Metz

Source :

Brain research [ 0006-8993 ] ; 2012.

RBID : Francis:12-0152281

Descripteurs français

Pascal (Inist)
- Epigenèse, Stress, Micro ARN, Méthylation, Maladie de Parkinson, Chorée de Huntington, Sclérose en plaques, Maladie dégénérative, Démence d'Alzheimer, Article synthèse.

English descriptors

KwdEn :
- Alzheimer disease, Degenerative disease, Epigenesis, Huntington disease, Methylation, Micro RNA, Multiple sclerosis, Parkinson disease, Review, Stress.

Abstract

Experience and environment can critically influence the risk and progression of neurodegenerative disorders. Epigenetic mechanisms, such as miRNA expression, DNA methylation, and histone modifications, readily respond to experience and environmental factors. Here we propose that epigenetic regulation of gene expression and environmental modulation thereof may play a key role in the onset and course of common neurological conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. For example, epigenetic mechanisms may mediate long-term responses to adverse experience, such as stress, to affect disease susceptibility and the course of neurodegenerative events. This review introduces the epigenetic components and their possible role in mediating neuropathological processes in response to stress. We argue that epigenetic modifications will affect neurodegenerative events through altered gene function. The study of epigenetic states in neurodegenerative diseases presents an opportunity to gain new insights into risk factors and pathogenic mechanisms. Moreover, research into epigenetic regulation of disease may revolutionize health care by opening new avenues of personalized, preventive and curative medicine.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0006-8993`
A02	`01`			`@0 BRREAP`
A03		`1`		`@0 Brain res.`
A05				`@2 1444`
A08	`01`	`1`	`ENG`	`@1 Epigenetic programming of neurodegenerative diseases by an adverse environment`
A11	`01`	`1`		`@1 BABENKO (Olena)`
A11	`02`	`1`		`@1 KOVALCHUK (Igor)`
A11	`03`	`1`		`@1 METZ (Gerlinde A.)`
A14	`01`			`@1 Department of Biological Sciences, University of Lethbridge @2 Lethbridge, Alberta @3 CAN @Z 1 aut. @Z 2 aut.`
A14	`02`			`@1 Canadian Centre for Behavioural Neuroscience, University of Lethbridge @2 Lethbridge, Alberta @3 CAN @Z 1 aut. @Z 3 aut.`
A20				`@1 96-111`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 12895 @5 354000508472020110`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 5 p.1/4`
A47	`01`	`1`		`@0 12-0152281`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Brain research`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 Experience and environment can critically influence the risk and progression of neurodegenerative disorders. Epigenetic mechanisms, such as miRNA expression, DNA methylation, and histone modifications, readily respond to experience and environmental factors. Here we propose that epigenetic regulation of gene expression and environmental modulation thereof may play a key role in the onset and course of common neurological conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. For example, epigenetic mechanisms may mediate long-term responses to adverse experience, such as stress, to affect disease susceptibility and the course of neurodegenerative events. This review introduces the epigenetic components and their possible role in mediating neuropathological processes in response to stress. We argue that epigenetic modifications will affect neurodegenerative events through altered gene function. The study of epigenetic states in neurodegenerative diseases presents an opportunity to gain new insights into risk factors and pathogenic mechanisms. Moreover, research into epigenetic regulation of disease may revolutionize health care by opening new avenues of personalized, preventive and curative medicine.
C02	`01`	`X`		`@0 770D03M @1 IV`
C03	`01`	`X`	`FRE`	`@0 Epigenèse @5 01`
C03	`01`	`X`	`ENG`	`@0 Epigenesis @5 01`
C03	`01`	`X`	`SPA`	`@0 Epigénesis @5 01`
C03	`02`	`X`	`FRE`	`@0 Stress @5 02`
C03	`02`	`X`	`ENG`	`@0 Stress @5 02`
C03	`02`	`X`	`SPA`	`@0 Estrés @5 02`
C03	`03`	`X`	`FRE`	`@0 Micro ARN @5 03`
C03	`03`	`X`	`ENG`	`@0 Micro RNA @5 03`
C03	`03`	`X`	`SPA`	`@0 Micro ARN @5 03`
C03	`04`	`X`	`FRE`	`@0 Méthylation @5 04`
C03	`04`	`X`	`ENG`	`@0 Methylation @5 04`
C03	`04`	`X`	`SPA`	`@0 Metilación @5 04`
C03	`05`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 05`
C03	`05`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 05`
C03	`05`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 05`
C03	`06`	`X`	`FRE`	`@0 Chorée de Huntington @5 06`
C03	`06`	`X`	`ENG`	`@0 Huntington disease @5 06`
C03	`06`	`X`	`SPA`	`@0 Corea Huntington @5 06`
C03	`07`	`X`	`FRE`	`@0 Sclérose en plaques @2 NM @5 07`
C03	`07`	`X`	`ENG`	`@0 Multiple sclerosis @2 NM @5 07`
C03	`07`	`X`	`SPA`	`@0 Esclerosis en placa @2 NM @5 07`
C03	`08`	`X`	`FRE`	`@0 Maladie dégénérative @5 09`
C03	`08`	`X`	`ENG`	`@0 Degenerative disease @5 09`
C03	`08`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 09`
C03	`09`	`X`	`FRE`	`@0 Démence d'Alzheimer @5 12`
C03	`09`	`X`	`ENG`	`@0 Alzheimer disease @5 12`
C03	`09`	`X`	`SPA`	`@0 Demencia Alzheimer @5 12`
C03	`10`	`X`	`FRE`	`@0 Article synthèse @5 57`
C03	`10`	`X`	`ENG`	`@0 Review @5 57`
C03	`10`	`X`	`SPA`	`@0 Artículo síntesis @5 57`
C07	`01`	`X`	`FRE`	`@0 Silence expression génique`
C07	`01`	`X`	`ENG`	`@0 Gene silencing`
C07	`01`	`X`	`SPA`	`@0 Silencio expresión genética`
C07	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 20`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 20`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 20`
C07	`03`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 21`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 21`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 21`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 22`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 22`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 22`
C07	`05`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 23`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 23`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 23`
C07	`06`	`X`	`FRE`	`@0 Maladie héréditaire @5 24`
C07	`06`	`X`	`ENG`	`@0 Genetic disease @5 24`
C07	`06`	`X`	`SPA`	`@0 Enfermedad hereditaria @5 24`
C07	`07`	`X`	`FRE`	`@0 Maladie inflammatoire @5 25`
C07	`07`	`X`	`ENG`	`@0 Inflammatory disease @5 25`
C07	`07`	`X`	`SPA`	`@0 Enfermedad inflamatoria @5 25`
N21				`@1 114`

Format Inist (serveur)

NO :	FRANCIS 12-0152281 INIST
ET :	Epigenetic programming of neurodegenerative diseases by an adverse environment
AU :	BABENKO (Olena); KOVALCHUK (Igor); METZ (Gerlinde A.)
AF :	Department of Biological Sciences, University of Lethbridge/Lethbridge, Alberta/Canada (1 aut., 2 aut.); Canadian Centre for Behavioural Neuroscience, University of Lethbridge/Lethbridge, Alberta/Canada (1 aut., 3 aut.)
DT :	Publication en série; Niveau analytique
SO :	Brain research; ISSN 0006-8993; Coden BRREAP; Pays-Bas; Da. 2012; Vol. 1444; Pp. 96-111; Bibl. 5 p.1/4
LA :	Anglais
EA :	Experience and environment can critically influence the risk and progression of neurodegenerative disorders. Epigenetic mechanisms, such as miRNA expression, DNA methylation, and histone modifications, readily respond to experience and environmental factors. Here we propose that epigenetic regulation of gene expression and environmental modulation thereof may play a key role in the onset and course of common neurological conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. For example, epigenetic mechanisms may mediate long-term responses to adverse experience, such as stress, to affect disease susceptibility and the course of neurodegenerative events. This review introduces the epigenetic components and their possible role in mediating neuropathological processes in response to stress. We argue that epigenetic modifications will affect neurodegenerative events through altered gene function. The study of epigenetic states in neurodegenerative diseases presents an opportunity to gain new insights into risk factors and pathogenic mechanisms. Moreover, research into epigenetic regulation of disease may revolutionize health care by opening new avenues of personalized, preventive and curative medicine.
CC :	770D03M
FD :	Epigenèse; Stress; Micro ARN; Méthylation; Maladie de Parkinson; Chorée de Huntington; Sclérose en plaques; Maladie dégénérative; Démence d'Alzheimer; Article synthèse
FG :	Silence expression génique; Pathologie du système nerveux; Pathologie de l'encéphale; Pathologie du système nerveux central; Syndrome extrapyramidal; Maladie héréditaire; Maladie inflammatoire
ED :	Epigenesis; Stress; Micro RNA; Methylation; Parkinson disease; Huntington disease; Multiple sclerosis; Degenerative disease; Alzheimer disease; Review
EG :	Gene silencing; Nervous system diseases; Cerebral disorder; Central nervous system disease; Extrapyramidal syndrome; Genetic disease; Inflammatory disease
SD :	Epigénesis; Estrés; Micro ARN; Metilación; Parkinson enfermedad; Corea Huntington; Esclerosis en placa; Enfermedad degenerativa; Demencia Alzheimer; Artículo síntesis
LO :	INIST-12895.354000508472020110
ID :	12-0152281

Links to Exploration step

Francis:12-0152281

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Epigenetic programming of neurodegenerative diseases by an adverse environment</title>
<author><name sortKey="Babenko, Olena" sort="Babenko, Olena" uniqKey="Babenko O" first="Olena" last="Babenko">Olena Babenko</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Biological Sciences, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Canadian Centre for Behavioural Neuroscience, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kovalchuk, Igor" sort="Kovalchuk, Igor" uniqKey="Kovalchuk I" first="Igor" last="Kovalchuk">Igor Kovalchuk</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Biological Sciences, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Metz, Gerlinde A" sort="Metz, Gerlinde A" uniqKey="Metz G" first="Gerlinde A." last="Metz">Gerlinde A. Metz</name>
<affiliation><inist:fA14 i1="02"><s1>Canadian Centre for Behavioural Neuroscience, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0152281</idno>
<date when="2012">2012</date>
<idno type="stanalyst">FRANCIS 12-0152281 INIST</idno>
<idno type="RBID">Francis:12-0152281</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000260</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Epigenetic programming of neurodegenerative diseases by an adverse environment</title>
<author><name sortKey="Babenko, Olena" sort="Babenko, Olena" uniqKey="Babenko O" first="Olena" last="Babenko">Olena Babenko</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Biological Sciences, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Canadian Centre for Behavioural Neuroscience, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kovalchuk, Igor" sort="Kovalchuk, Igor" uniqKey="Kovalchuk I" first="Igor" last="Kovalchuk">Igor Kovalchuk</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Biological Sciences, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Metz, Gerlinde A" sort="Metz, Gerlinde A" uniqKey="Metz G" first="Gerlinde A." last="Metz">Gerlinde A. Metz</name>
<affiliation><inist:fA14 i1="02"><s1>Canadian Centre for Behavioural Neuroscience, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Brain research</title>
<title level="j" type="abbreviated">Brain res.</title>
<idno type="ISSN">0006-8993</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Brain research</title>
<title level="j" type="abbreviated">Brain res.</title>
<idno type="ISSN">0006-8993</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer disease</term>
<term>Degenerative disease</term>
<term>Epigenesis</term>
<term>Huntington disease</term>
<term>Methylation</term>
<term>Micro RNA</term>
<term>Multiple sclerosis</term>
<term>Parkinson disease</term>
<term>Review</term>
<term>Stress</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Epigenèse</term>
<term>Stress</term>
<term>Micro ARN</term>
<term>Méthylation</term>
<term>Maladie de Parkinson</term>
<term>Chorée de Huntington</term>
<term>Sclérose en plaques</term>
<term>Maladie dégénérative</term>
<term>Démence d'Alzheimer</term>
<term>Article synthèse</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Experience and environment can critically influence the risk and progression of neurodegenerative disorders. Epigenetic mechanisms, such as miRNA expression, DNA methylation, and histone modifications, readily respond to experience and environmental factors. Here we propose that epigenetic regulation of gene expression and environmental modulation thereof may play a key role in the onset and course of common neurological conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. For example, epigenetic mechanisms may mediate long-term responses to adverse experience, such as stress, to affect disease susceptibility and the course of neurodegenerative events. This review introduces the epigenetic components and their possible role in mediating neuropathological processes in response to stress. We argue that epigenetic modifications will affect neurodegenerative events through altered gene function. The study of epigenetic states in neurodegenerative diseases presents an opportunity to gain new insights into risk factors and pathogenic mechanisms. Moreover, research into epigenetic regulation of disease may revolutionize health care by opening new avenues of personalized, preventive and curative medicine.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0006-8993</s0>
</fA01>
<fA02 i1="01"><s0>BRREAP</s0>
</fA02>
<fA03 i2="1"><s0>Brain res.</s0>
</fA03>
<fA05><s2>1444</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG"><s1>Epigenetic programming of neurodegenerative diseases by an adverse environment</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BABENKO (Olena)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KOVALCHUK (Igor)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>METZ (Gerlinde A.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Biological Sciences, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Canadian Centre for Behavioural Neuroscience, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>96-111</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>12895</s2>
<s5>354000508472020110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>5 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0152281</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Brain research</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Experience and environment can critically influence the risk and progression of neurodegenerative disorders. Epigenetic mechanisms, such as miRNA expression, DNA methylation, and histone modifications, readily respond to experience and environmental factors. Here we propose that epigenetic regulation of gene expression and environmental modulation thereof may play a key role in the onset and course of common neurological conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. For example, epigenetic mechanisms may mediate long-term responses to adverse experience, such as stress, to affect disease susceptibility and the course of neurodegenerative events. This review introduces the epigenetic components and their possible role in mediating neuropathological processes in response to stress. We argue that epigenetic modifications will affect neurodegenerative events through altered gene function. The study of epigenetic states in neurodegenerative diseases presents an opportunity to gain new insights into risk factors and pathogenic mechanisms. Moreover, research into epigenetic regulation of disease may revolutionize health care by opening new avenues of personalized, preventive and curative medicine.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>770D03M</s0>
<s1>IV</s1>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Epigenèse</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Epigenesis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Epigénesis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Stress</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Stress</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Estrés</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Micro ARN</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Micro RNA</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Micro ARN</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Méthylation</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Methylation</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Metilación</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Chorée de Huntington</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Huntington disease</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Corea Huntington</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Sclérose en plaques</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Multiple sclerosis</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Esclerosis en placa</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Démence d'Alzheimer</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Alzheimer disease</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Demencia Alzheimer</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>57</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Review</s0>
<s5>57</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>57</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Silence expression génique</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Gene silencing</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Silencio expresión genética</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>20</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>21</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>21</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>21</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>22</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>22</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>22</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>23</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>23</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>23</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie héréditaire</s0>
<s5>24</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Genetic disease</s0>
<s5>24</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad hereditaria</s0>
<s5>24</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Maladie inflammatoire</s0>
<s5>25</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Inflammatory disease</s0>
<s5>25</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Enfermedad inflamatoria</s0>
<s5>25</s5>
</fC07>
<fN21><s1>114</s1>
</fN21>
</pA>
</standard>
<server><NO>FRANCIS 12-0152281 INIST</NO>
<ET>Epigenetic programming of neurodegenerative diseases by an adverse environment</ET>
<AU>BABENKO (Olena); KOVALCHUK (Igor); METZ (Gerlinde A.)</AU>
<AF>Department of Biological Sciences, University of Lethbridge/Lethbridge, Alberta/Canada (1 aut., 2 aut.); Canadian Centre for Behavioural Neuroscience, University of Lethbridge/Lethbridge, Alberta/Canada (1 aut., 3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Brain research; ISSN 0006-8993; Coden BRREAP; Pays-Bas; Da. 2012; Vol. 1444; Pp. 96-111; Bibl. 5 p.1/4</SO>
<LA>Anglais</LA>
<EA>Experience and environment can critically influence the risk and progression of neurodegenerative disorders. Epigenetic mechanisms, such as miRNA expression, DNA methylation, and histone modifications, readily respond to experience and environmental factors. Here we propose that epigenetic regulation of gene expression and environmental modulation thereof may play a key role in the onset and course of common neurological conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. For example, epigenetic mechanisms may mediate long-term responses to adverse experience, such as stress, to affect disease susceptibility and the course of neurodegenerative events. This review introduces the epigenetic components and their possible role in mediating neuropathological processes in response to stress. We argue that epigenetic modifications will affect neurodegenerative events through altered gene function. The study of epigenetic states in neurodegenerative diseases presents an opportunity to gain new insights into risk factors and pathogenic mechanisms. Moreover, research into epigenetic regulation of disease may revolutionize health care by opening new avenues of personalized, preventive and curative medicine.</EA>
<CC>770D03M</CC>
<FD>Epigenèse; Stress; Micro ARN; Méthylation; Maladie de Parkinson; Chorée de Huntington; Sclérose en plaques; Maladie dégénérative; Démence d'Alzheimer; Article synthèse</FD>
<FG>Silence expression génique; Pathologie du   système nerveux; Pathologie de l'encéphale; Pathologie du système nerveux central; Syndrome extrapyramidal; Maladie héréditaire; Maladie inflammatoire</FG>
<ED>Epigenesis; Stress; Micro RNA; Methylation; Parkinson disease; Huntington disease; Multiple sclerosis; Degenerative disease; Alzheimer disease; Review</ED>
<EG>Gene silencing; Nervous system diseases; Cerebral disorder; Central nervous system disease; Extrapyramidal syndrome; Genetic disease; Inflammatory disease</EG>
<SD>Epigénesis; Estrés; Micro ARN; Metilación; Parkinson enfermedad; Corea Huntington; Esclerosis en placa; Enfermedad degenerativa; Demencia Alzheimer; Artículo síntesis</SD>
<LO>INIST-12895.354000508472020110</LO>
<ID>12-0152281</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000260 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000260 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Francis:12-0152281
   |texte=   Epigenetic programming of neurodegenerative diseases by an adverse environment
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Epigenetic programming of neurodegenerative diseases by an adverse environment

Epigenetic programming of neurodegenerative diseases by an adverse environment

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri